SELLAS Life Sciences Group Target of Unusually Large Options Trading (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the target of unusually large options trading on Monday. Stock investors bought 42,324 call options on the company. This represents an increase of approximately 54% compared to the typical volume of 27,474 call options.

SELLAS Life Sciences Group Price Performance

Shares of NASDAQ:SLS traded up $0.43 on Monday, hitting $4.58. 7,322,775 shares of the company’s stock were exchanged, compared to its average volume of 8,705,112. The stock has a market capitalization of $651.66 million, a price-to-earnings ratio of -16.38 and a beta of 2.27. The business’s 50 day simple moving average is $3.66 and its two-hundred day simple moving average is $2.42. SELLAS Life Sciences Group has a 12 month low of $0.95 and a 12 month high of $5.18.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Grange Capital LLC raised its stake in SELLAS Life Sciences Group by 18.5% in the fourth quarter. Grange Capital LLC now owns 16,001 shares of the company’s stock valued at $60,000 after buying an additional 2,500 shares in the last quarter. Invesco Ltd. raised its position in shares of SELLAS Life Sciences Group by 6.2% during the 4th quarter. Invesco Ltd. now owns 53,293 shares of the company’s stock worth $201,000 after acquiring an additional 3,114 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in shares of SELLAS Life Sciences Group by 13.6% during the 4th quarter. The Manufacturers Life Insurance Company now owns 38,018 shares of the company’s stock worth $143,000 after acquiring an additional 4,564 shares in the last quarter. Equitable Holdings Inc. lifted its stake in SELLAS Life Sciences Group by 18.5% during the fourth quarter. Equitable Holdings Inc. now owns 32,060 shares of the company’s stock worth $121,000 after purchasing an additional 5,000 shares during the last quarter. Finally, ProShare Advisors LLC boosted its holdings in SELLAS Life Sciences Group by 31.5% in the fourth quarter. ProShare Advisors LLC now owns 22,638 shares of the company’s stock valued at $85,000 after purchasing an additional 5,417 shares in the last quarter. 17.38% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, SELLAS Life Sciences Group presently has an average rating of “Hold” and an average target price of $7.00.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.